Index 
 Previous 
 Next 
 Full text 
Procedure : 2012/0192(COD)
Document stages in plenary
Document selected : A7-0208/2013

Texts tabled :

A7-0208/2013

Debates :

PV 02/04/2014 - 15
CRE 02/04/2014 - 15

Votes :

PV 02/04/2014 - 18.18
Explanations of votes

Texts adopted :

P7_TA(2014)0273

Minutes
Wednesday, 2 April 2014 - Brussels

15. Clinical trials on medicinal products for human use (debate)
CRE

Report on the proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC [COM(2012)0369 - C7-0194/2012 - 2012/0192(COD)] - Committee on the Environment, Public Health and Food Safety. Rapporteur: Glenis Willmott (A7-0208/2013)

Glenis Willmott introduced the report.

The following spoke: Tonio Borg (Member of the Commission).

The following spoke: Philippe Juvin, on behalf of the PPE Group, Antonyia Parvanova (rapporteur for the opinion of the IMCO Committee), Gilles Pargneaux, on behalf of the S&D Group, Margrete Auken, on behalf of the Verts/ALE Group, Milan Cabrnoch, on behalf of the ECR Group, Alda Sousa, on behalf of the GUE/NGL Group, and Claudio Morganti, on behalf of the EFD Group.

IN THE CHAIR: Rainer WIELAND
Vice-President

The following spoke: Peter Liese.

The following spoke under the 'catch-the-eye' procedure: Christa Klaß, António Fernando Correia de Campos, Ruža Tomašić, Maria do Céu Patrão Neves and Biljana Borzan

The following spoke: Tonio Borg and Glenis Willmott.

The debate closed.

Vote: minutes of 2.4.2014, item 18.18.

Legal notice - Privacy policy